COTA, Inc. and Kite Collaborate To Expand the Use of Real-World Data To Drive Faster, Effective Treatments for Cancers

COTA’s Real-World Data Will Complement Single-Arm Clinical Trials to Accelerate Cancer Research Benefiting Patients

COTA, Inc., an oncology real-world data and analytics company, announced a collaboration with Kite, a Gilead company, through which COTA’s real-world data will be used to accelerate Kite’s drug development pipeline. This approach will help inform decisions about future therapeutic applications for blood cancers while inspiring new ways of thinking about how clinical trials are designed.

The use of real-world data (RWD) is expanding as it is increasingly used in a complementary role to support, clarify, or accelerate randomized clinical trials. Kite will work closely with oncologists, data scientists, and researchers at COTA to develop and validate real-world endpoints and accelerate the clinical development timeline for patient benefit.

Recommended AI News: Moovila and Raven Intel Join Forces to Provide a Risk-Eliminating Resource for Selecting Software Solution Providers

“At COTA, we pride ourselves not just on the high quality of the data we deliver to our partners, but also on our ability to collaborate with sponsors to inform clinical research and get the best drugs to patients more efficiently,” said Mike Doyle, CEO of COTA. “With the support of the FDA, Kite and many others, COTA is helping to pioneer the use of RWD in clinical research with the ultimate goal of accelerating clinical development, reducing healthcare costs, and helping cancer patients live longer, healthier lives.”

Recommended AI News: Sierra Wireless Appoints James Armstrong Senior Vice President and General Manager, Enterprise Solutions

COTA provides comprehensive and diverse cancer RWD to leading life sciences and healthcare provider organizations that are caring and developing treatments for patients living with a wide range of cancers. COTA uniquely combines its oncology expertise with technology-enabled human data abstraction to curate meaningful, longitudinal, and de-identified patient data. As RWD is increasingly applied in clinical development, COTA’s customized data sets can help increase patient diversity in clinical trials; expand indications of already approved drugs; replace the traditional standard-of-care or placebo group via a RWD-powered synthetic control arm; and empower life sciences companies to make faster decisions on their pipeline.

Recommended AI News: HARMAN Reimagines the In-Vehicle Experience Through Expanded HARMAN ExP Technology Suite